Search results
5 Top Stocks to Buy in June
The Motley Fool via AOL· 58 minutes agoPharmaceuticals): With all due respect to Larry David, I can't curb my enthusiasm about Vertex Pharmaceuticals. This big biotech has so much going for it...
Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock
Zacks via Yahoo Finance· 5 days agoACRV beat estimates in three of the trailing four quarters and missed the mark once, delivering an...
BioMarin Pharmaceutical (NASDAQ:BMRN) shareholders have endured a 15% loss from investing in the...
Simply Wall St. via Yahoo Finance· 6 days agoUnfortunately the BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) share price slid 15% over twelve...
US Bancorp DE Has $4.34 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
ETF DAILY NEWS· 4 days ago(NASDAQ:REGN – Free Report) by 6.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional ...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Commerce Bank
ETF DAILY NEWS· 6 days agoReport) by 7.7% in the fourth quarter, HoldingsChannel.com reports. The fund owned 36,569 shares of the biotechnology company’s stock after selling 3,050 shares during the ...
Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY®
Clearfield Progress· 3 days agoVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that ownership of the U.S. New Drug Application and Investigational New Drug Applications for PONVORY® (ponesimod ...
The 2024 Millionaire's Club: 3 Penny Stocks to Buy Now
InvestorPlace· 2 days agoOne of the best ways to spot opportunities in penny stocks to buy is by following insiders. After...
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Zacks via Yahoo Finance· 5 days agoThe size of the recent change in the consensus estimate, along with three other factors related to...
Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study
Zacks· 2 days agoUltragenyx (RARE) reports meeting primary and secondary endpoints in the late-stage study of its investigational gene therapy, DTX401, to treat glycogen storage disease type Ia.
Principal Financial Group Inc. Sells 3,337 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
ETF DAILY NEWS· 5 days agoPrincipal Financial Group Inc. decreased its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 1.1% during the 4th quarter, according ...
